NCT05876806View on ClinicalTrials.gov

Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene Alterations

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 20, 2023

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Cancer
Interventions
DRUG

Dabrafenib

Dabrafenib is a 150 mg twice daily capsule administered orally on a continuous basis

DRUG

Trametinib

Trametinib is a 2 mg once daily tablet administered orally on a continuous basis.

Trial Locations (1)

06591

RECRUITING

Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul

All Listed Sponsors
lead

Se Jun Park

OTHER